ABSTRACT
Background: Increased intracranial pressure (ICP) is a known complication of pre-eclampsia with severe features. The use of magnesium sulphate (MgSO4) is the standard treatment and is associated with marked reduction of cerebral perfusion pressure (CPP) and prevention of cerebral damage. Optic nerve sheath diameter (ONSD) ultrasonography is a bedside tool used to reflect changes in the ICP. The aim of this study is to detect the effect of MgSO4 administration on ICP in severe preeclampsia through measuring changes in the ONSD.
Methods: Thirty pregnant female patients suffering from severe pre-eclampsia were enrolled in this prospective pilot study. Ultrasound measurement of ONSD was measured before the commencement of MgSO4 and after 1, 6, and 24 h after the administration.
Results: There was a significant difference in ONSD measurements between that at baseline and post magnesium administration at 1, 6, and 24 h (P-value 0.001). Additionally, a significant difference in measurements between 1 and 6 and 6 and 24 h after magnesium initiation (P-value 0.001).
Conclusions: Ultrasound ONSD measurement in patients with severe preeclampsia is a non-invasive easy tool to detect increased intracranial pressure and monitor the response to magnesium sulphate infusion.

Key words: Magnesium sulphate; optic nerve diameter sheath; preeclampsia

Introduction
Preeclampsia remains one of the leading causes of maternal morbidity and mortality in pregnant women. Cerebrovascular complications are one of the serious problems in severe preeclampsia. Cerebral edema detected by MRI imaging has been reported to be as high as 71–100% in patients suffering from severe preeclampsia.[1–3] Early diagnosis and management of brain edema and increased intracranial pressure (ICP) is of paramount importance.[4]

The optic nerve with its dural sheath cover is considered a window to central nervous system. The subarachnoid space surrounds the optic nerve and communicates freely with the cerebral subarachnoid space. Changes in the optic...
nerve sheath diameter (ONSD) mirror the changes in the ICP as increases in the ONSD correlates with increase in the ICP.\textsuperscript{[5]} Bedside ultrasound measurement of the optic nerve has proved to be a simple and effective diagnostic tool to detect the increase in ICP in traumatic and critically ill patients.\textsuperscript{[6]} Recently, ONSD is used in patients suffering from preeclampsia.\textsuperscript{[4,7,8]} Researchers showed that changes in ONSD strongly correlate with computed tomography and MRI measurements in patients diagnosed with traumatic brain injury (TBI) and high ICP.\textsuperscript{[9,11]} A meta-analysis showed a 99% sensitivity and 73% specificity in detecting increased ICP when the ONSD is >5.0 mm.\textsuperscript{[8]} However, some authors decided to use ONSD of 5.8 mm as cutoff measurement to detect increased ICP in patients suffering from pre-eclampsia.\textsuperscript{[6,7]}

Magnesium sulphate (MgSO\textsubscript{4}) is a drug that is routinely used in the treatment of preeclampsia and prevention of eclamptic fits.\textsuperscript{[12]} Magnesium stabilizes the nerve axons by stimulating the release of glutamate at the neuromuscular junction, thus inhibiting calcium entry at the presynaptic nerve terminal.\textsuperscript{[13]} A previous work showed a significant association between the magnesium usage and the decrease in intraoperative brain swelling in patients who suffered severe closed traumatic brain injury.\textsuperscript{[14]} Another work used transcranial Doppler (TCD) to demonstrated the effect of MgSO\textsubscript{4} on the cerebral perfusion pressure in patients suffering from severe pre-eclampsia and eclampsia.\textsuperscript{[15]}

The aim of this study is to determine the effect of MgSO\textsubscript{4} on ultrasound measurements of the ONSD as a surrogate measure to intracranial pressure in patients presented with severe preeclampsia.

**Methods**

Corniche hospital, Abu Dhabi, United Arab Emirates research ethics committee provided ethical approval for this study CH29011702. The study was registered with a clinical trial registry clinicaltrial.gov (number NCT032110350) prior to patient enrolment. Written informed consent was obtained for all patients. This study is an observational study according to the guidelines for strengthening the reporting of observational studied in epidemiology (STROBE).

Thirty pregnant patients who fulfilled the inclusion criteria of preeclampsia with severe features, as was defined using the American College of Obstetricians and Gynecologist Task Force on Hypertension in Pregnancy recommendation were recruited in this prospective pilot study.\textsuperscript{[16]} Patients with previous cranial or eye surgeries, or suffering from intracranial pathology, glaucoma, or other eye pathology were excluded from the study. Additionally, patient who got their MgSO\textsubscript{4} medication before the first reading of ONSD were also excluded.

As per our institution’s standard protocol, all pre-eclamptic patients on MgSO\textsubscript{4} were admitted to high dependency Unit (HDU) for at least 24 h. Invasive blood pressure continuously measured, fluid intake, and urine output were assessed hourly. Blood tests were repeated every 12 h to monitor kidney function, electrolytes, full blood count, liver transaminases, and bilirubin. MgSO\textsubscript{4} was used for eclampsia prophylaxis as a 4 g intravenous loading dose, followed by 1 g/h infusion for 24 h. The study patients were recruited at the time of admission in HDU or Emergency suite. Once the decision was made to start MgSO\textsubscript{4} the ONSD was measured during the time of MgSO\textsubscript{4} preparation to avoid any delay for the initiation of the treatment. Intravenous antihypertensive medications were started also according to our institution policy to keep systolic blood pressure <160 mmHg and diastolic blood pressure <110 mmHg. Measurements of ONSD were repeated 1 h after finishing the MgSO\textsubscript{4} loading dose, 6 and 24 h after the start of infusion.

Patients were in the supine position with the head of the bed was less than 20° elevation. A high frequency (7.5 MHz) linear probe of Terson uSmart 3200T was used. The thermal index was kept less than 0.8 and the time of application was between 30 and 60 s to avoid any possible eye injury. The probe was placed gently over each closed eye after liberal application of a sterile gel, the patients were instructed to look forward aligning the optic nerve directly opposite to the probe. The ONSD was measured 3 mm behind the optic disc in both the sagittal and transverse planes of each eye and then an average was calculated and recorded. The ONSD measurement ≥5.8 mm was used as a cutoff point to determine increased in the ICP. Hemodynamic variables were recorded at the same times.

**Statistical analysis**

The results were analyzed using the Statistical Package for Social Science (IBM SPSS Statistics for Macintosh, Version 20.0. Armonk, NY, USA). Normality was tested by Shapiro–Wilks’s test. The paired t-test was used to compare the mean of average ONDS at the 4 points of measurements. P value for this measurement was set on 0.0125 to reduce the risk of type I error (Bonferroni correction). As a post-hoc analysis, linear regression was done between ONSD and mean arterial pressure (MAP) at all predetermined measurements points. Numerical data are presented as mean and SD or confidence interval whenever appropriate.
**Results**

This study included a total of 30 parturient with severe preeclampsia. Patients with an average age 31.9 ± 5.9 years (range 19–43 years), with a mean gestational age 31.8 ± 5.9 weeks (range 22–40 weeks) and body mass index (BMI) 33.5 ± 6.0 kg/m² (range 22.3–47.8 kg/m²). Preeclampsia presentation, mode of delivery, and anesthesia technique are presented in [Table 1]. Data were normality distributed as Shapiro–Wilk’s test for normality was statistically insignificant ($P > 0.05$).

The paired $t$-test was used to compare the mean of average ONDS before and after administration of MgSO$_4$ [Table 2]. There was a significant difference at ONDS from the baseline at 1, 6, and 24 h after MgSO$_4$ administration with $P$ value of 0.000 [Figure 1]. A second set of comparison of ONDS done between 1 and 6 h and 6 and 24 h from MgSO$_4$ administration, these compressions were statistically significant with a $P$ value of 0.000.

A simple linear regression was performed to predict the correlation between ONDS and MAP at all predetermined measuring points. At the baseline measurement insignificant regression equation was found ($F (1,28) = 1.35, P 0.254$), with an $R^2$ of 0.046. At 1 h of measurement; insignificant regression was found with equation ($F (1,28) = 0.042, P 0.839$), with an $R^2$ of 0.034. Furthermore; correlation done at 6 h were insignificant with regression equation of ($F (1,28) = 0.326, P 0.573$), with an $R^2$ of -0.024. At 24 h, the regression was insignificant with the following equation ($F (1,28) = 0.014, P 0.905$), with an $R^2$ of -0.035. All of this is indicative of negative correlation between drop in ONDS and MAP.

**Discussion**

The present work demonstrated that ONSD could be used to detect an increase in the ICP and monitor the effect of magnesium in patients with severe preeclampsia. The study also showed that there was no correlation between the ONSD and MAP at any measured time point.

Baseline measurements of ONSD was marked increase in all parturient participated in the current study, this was in the agreement with previous work done by Simenc et al., Aduagi et al., Singh and Bhatia, and Bala et al. that showed the correlation between increased ICP and increased ONSD in patients suffering preeclampsia and eclampsia when they used ultrasound technique.[4,7,8,17] Furthermore, increased ICP was also supported by MRI in a studies carried out by Loureiro et al., Schwartz et al., and Zeeman et al. that showed evidence of brain edema in 100%, 71%, and 92%, respectively, in patients suffering from eclampsia and severe preeclampsia.[1-3]

**Table 1: Patients presentation, Mode of delivery and anesthesia technique**

|                      | Number (percent) |
|----------------------|------------------|
| **Preclampsia presentation:** |                  |
| Neurological manifestations | 21 (70)          |
| Eclamptic fit before admission | 1 (3)            |
| Abdominal pain | 10 (33%)         |
| HELLP syndrome | 3 (10%)          |
| Postnatal preeclampsia | 3 (10%)          |
| **Mode of delivery:** |                  |
| Cesarean section | 20 (67%)         |
| Vaginal delivery | 8 (27%)          |
| Intrauterine fetal death IUFD | 2 (7%)         |
| **Anesthesia technique:** |                  |
| Spinal anesthesia | 19 (63%)         |
| Epidural anesthesia | 3 (10%)          |
| General anesthesia | 3 (10%)          |
| Vaginal delivery without analgesia | 4 (13%) |
| Delivered outside our hospital | 1 (3%) |

**Table 2: Effect of magnesium sulphate on optic nerve diameter sheath**

|                      | Mean (SD) | 95% confidence interval | $t$ statistic (df) | $P$ |
|----------------------|-----------|-------------------------|-------------------|-----|
| **Time 1** | **Time 2** |                      |                   |     |
| Baseline ONDS & 1 h after magnesium | 0.67 (0.05) | 0.63 (0.04) | 0.018 - 0.05 | 4.12 (29) | 0.000 |
| Baseline ONDS & 6 h after magnesium | 0.67 (0.05) | 0.53 (0.04) | 0.018 - 0.15 | 11.3 (29) | 0.000 |
| Baseline ONDS & 24 h after magnesium | 0.67 (0.05) | 0.49 (0.03) | 0.15 – 0.02 | 15.4 (29) | 0.000 |
| ONDS 1 h & 6 h after magnesium | 0.63 (0.04) | 0.53 (0.04) | 0.08 – 0.11 | 14.0 (29) | 0.000 |
| ONDS 6 & 24 h after magnesium | 0.53 (0.04) | 0.49 (0.03) | 0.03 -0.05 | 8.7 (29) | 0.000 |

SD = Standard deviation & df = degree of freedom

Figure 1: Optic nerve diameter sheath (ONDS) over time
The diagnostic accuracy of ONSD was validated in patients with traumatic brain injury. A meta-analysis of Aduayi et al. documented that ONSD measurements of >5.0 mm can detect increased ICP by computed tomography (CT) with 99% sensitivity and 73% specificity.[6] Furthermore, another study compared ONSD by US to direct measurement of ICP showed that using 5.0 mm can be used as a cutoff limit to detect ICP >20 cm H₂O with 88% sensitivity and 93% specificity.[18]

In the current study, 5.8 mm was used as the cutoff point, based on the previous studies done on patients suffering preeclampsia and eclampsia.[6,7,17] The current study showed that ONSD measurements were above the cutoff point in 100% of patients compared to the study carried by Simenc et al. which showed a 43% of baseline ONSD measurement above the cutoff point.[4] This difference could be attributed to the difference in percentage of patients presented with neurological manifestations which is higher in our patients (70%) compared to 53% in Simenc study.

To our knowledge, this is the first study that attempts to correlate the relationship between MgSO₄ therapy and the ONSD as a surrogate to ICP in patients suffering from severe preeclampsia/eclampsia. A previous study by Dhandapani et al. used MgSO₄ in treatment of severe closed traumatic brain injury showed a significant decrease in intraoperative brain swelling and improved neurological output in relation to the control group.[14]

There are some limitations in our study. Firstly, the cofounding effect that antihypertensive drugs might have an effect on the ONSD measurements where it is unethical to withhold the antihypertensive drugs to such group of patients and this could also explain the negative correlation between drop in ONDS and MAP. Secondly, still the effect of the anesthesia on the ONSD needs further evaluation. Thirdly, there is no studied showed the correlation between ONSD and direct ICP measurements in patients suffering from pre-eclampsia, so most of the data used in the study were derived from previous work done on patients with traumatic brain injury.

Conclusions

Ultrasound ONSD measurement in patients with severe preeclampsia may provide a noninvasive, easy and reliable tool to detect increased intracranial pressure and to monitor the response to MgSO₄ therapy.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Loureiro R, Leite CC, Kahhale S, Freire S, Sousa B, Ellison F, et al. Diffusion imaging may predict reversible brain lesions in eclampsia and severe preeclampsia: Initial experience. Am J Obstet Gynecol 2003;189:1350-5.
2. Schwartz RB, Feske SK, Polak JF, DeGirolami U, Iaia A, Beckner KM, et al. Preeclampsia-eclampsia: Clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 2000;217:371-6.
3. Zeeman GG, Fleckenstein JL, Twickler DM, Cunningham FG. Cerebral infarction in eclampsia. Am J Obstet Gynecol 2004;190:714-20.
4. Brzan Simenc G, Ambrozic J, Prokselj K, Tul N, Cvijic M, Mirkovic T, et al. Ocular ultrasonography for diagnosing increased intracranial pressure in patients with severe preeclampsia. Int J Obstet Anesth 2018;36:49-55.
5. Aduayi OS, Asaleye CM, Adetiloye VA, Komolafe EO, Aduayi VA. Optic nervesonoigraphy: A noninvasive means of detecting raised intracranial pressure in a resource limited setting. J Neurosci Rural Pract 2015;6:563-7.
6. Kim SE, Hong EP, Kim HC, Lee SU, Jeon JP. Ultrasonographic optic nerve sheath diameter to detect increased intracranial pressure in adults: A meta-analysis. Acta Radiol 2019;60:221-9.
7. Dubost C, Le Gouez A, Jouffroy V, Roger-Christoph S, Benhamou D, Mercier FJ, et al. Optic nerve sheath diameter used as ultrasonographic assessment of the incidence of raised intracranial pressure in preeclampsia: A pilot study. Anesthesiology 2012;116:1066-71.
8. Singh SK, Bhatia K. Ultrasonographic optic nerve sheath diameter as a surrogate measure of raised intracranial pressure in severe pregnancy-induced hypertension patients. Anesth Essays Res 2018;12:42-6.
9. Goel RS, Goyal NK, Dharap SB, Kumar M, Gore MA. Utility of optic nerve ultrasonography in head injury. Injury 2008;39:519-24.
10. Soldatos T, Karakitsos D, Chatzimichail K, Papathanasiou M, Gouliamos A, Karabinis A. Optic nerve sonography in the diagnostic evaluation of adult brain injury. Crit Care 2008;12:R67.
11. Shirodkar CG, Munta K, Rao SM, Mahesh MU. Correlation of measurement of optic nerve sheath diameter using ultrasound with magnetic resonance imaging. Indian J Crit Care Med 2015;19:466-70.
12. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: A randomized placebo-controlled trial. Lancet 2002;359:1877-90.
13. Tong GM, Rude RK. Magnesium deficiency in critical illness. J Intensive Care Med 2005;20:3-17.
14. Dhandapani SS, Gupta A, Vivekanandhan S, Sharma BS, Mahapatra AK. Randomized controlled trial of magnesium sulphate in severe closed traumatic brain injury. Indian J Neurotrauma 2008;5:27-33.
15. Belfort M, Alred J, Dildy G. Magnesium sulfate decreases cerebral perfusion pressure in preeclampsia. Hypertens Pregnancy 2008;27:315-27.
16. American College of Obstetricians and Gynecologists. Hypertension in pregnancy: Executive summary. Obstet Gynecol 2013;122:1122-31.
17. Bala R, Banerjee A, Taxak S, Kumar R. Optic nerve sheath diameter measured using ocular sonography is raised in patients with eclampsia. J Obstet Anaesth Crit Care 2019;9:65-9.
18. Kimberly HH, Shah S, Marill K, Noble V. Correlation of optic nerve sheath diameter with direct measurement of intracranial pressure. Acad Emerg Med 2008;15:201-4.

Author Help: Online submission of the manuscripts

Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) **First Page File:**
Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) **Article File:**
The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) **Images:**
Submit good quality color images. Each image should be less than 4096 kb (4 MB) in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) **Legends:**
Legends for the figures/images should be included at the end of the article file.